Ace Investor Dolly Khanna increased her stake in Rama Phosphates Limited from 2.3% in the December quarter to 2.6% in the March quarter. She holds a total of 4,52,987 shares worth about ₹ 17.9 crores in the company.
The shares of Rama Phosphates have given multibagger returns of 304.87 % in the last five years. In the last year, the shares have given multibagger returns of 129.76 %. Since the beginning of this year, the shares have given 22.98 % returns. Today, its share price is up 2.64 % at ₹394.95 apiece.
If an investor would have invested ₹ 1,00,000 in the share only a year ago, they would have had holdings worth ₹2,29,760. Further, if they would have invested ₹1,00,000 about five years ago, and would have stayed invested, then they would have had holdings worth ₹4,04,870 today.
The company reported a 58.57% jump in its net sales from ₹ 151.42 crores in December 2020 to ₹ 240.10 crores in December 2021. Its quarterly net profit stood at ₹ 21.48 crores in December 2021 up 87.16% from ₹ 11.47 crores in December 2020.
A meeting of its board of directors is scheduled on 27/05/2022, inter alia, to consider and approve the Audited Financial Results for the quarter and fiscal year ended March 31, 2022, and to recommend a final dividend on equity shares for the financial year ended March 31, 2022, if any, as per a filing with the BSE.
Rama Phosphates is a small-cap company with a market capitalization of 683.1 Crore. Its PE Ratio is at 8.9, below the industry average. The company has an ideal debt to equity ratio of 0.03 and a good current ratio of 2.24. It has had a good average ROE of 15.32% for the last three years. The company’s average revenue growth for the last three years is 15.9%. Its net profit has grown by 98.43% over the last three years. It does not have pledged shares and its promoters hold a 75% stake in the company.
Disclaimer
The content in this news article is not investment advice. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
